Meeting
2014 ASCO Annual Meeting
Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib—LUX-Lung 5 (LL5).
Authors
Martin H. Schuler
West German Cancer Center, University Duisburg-Essen, Essen, Germany
Martin H. Schuler , Chih-Hsin Yang , Keunchil Park , Jaafar Bennouna , Yuh-Min Chen , Christos Chouaid , Filippo De Marinis , Ji Feng Feng , Francesco Grossi , Dong-Wan Kim , Xiaoqing Liu , Shun Lu , Janos Strausz , Yurii Vinnyk , Rainer Wiewrodt , Caicun Zhou , Vikram K. Chand , Bushi Wang , Joo-Hang Kim , David Planchard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01085136
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8019^)
DOI
10.1200/jco.2014.32.15_suppl.8019
Abstract #
8019^
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2022 ASCO Annual Meeting
Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
First Author: Likun Chen
Poster
2021 ASCO Quality Care Symposium
Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
First Author: Rahul Shenolikar